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Polyomaviruses are a family of small, nonenveloped viruses with a circular double-stranded DNA genome of ∼5,000 base pairs
protected by an icosahedral protein structure. So far, members of this family have been identiﬁed in birds and mammals. Until
2006, BK virus (BKV), JC virus (JCV), and simian virus 40 (SV40) were the only polyomaviruses known to circulate in the human
population. Their occurrence in individuals was mainly conﬁrmed by PCR and the presence of virus-speciﬁc antibodies. Using the
samemethods,lymphotropicpolyomavirus,originallyisolatedinmonkeys,wasrecentlyshowntobepresentinhealthyindividuals
although with much lower incidence than BKV, JCV, and SV40. The use of advanced high-throughput sequencing and improved
rollingcircleampliﬁcationtechniqueshaveidentiﬁedthenovelhumanpolyomavirusesKI,WU,Merkelcellpolyomavirus,HPyV6,
HPyV7, trichodysplasia spinulosa-associated polyomavirus, and HPyV9. The skin tropism of human polyomaviruses and their
dermatopathologic potentials are the focus of this paper.
1.Introduction
Polyomaviruses (PyV) were ﬁrst described in 1953 in mice,
but have since then been detected in diﬀerent bird species,
cattle, bats, rabbits, hamster, sea lion, monkeys from the Old
and New World, and humans [1, 2]. Their name (Greek poly
means many, and oma refers to cancer) is derived from the
factthattheﬁrstknownpolyomavirus,mousepolyomavirus,
wasabletoinduceawiderangeoftumoursinmice(reviewed
in [3]). Members of the Polyomaviridae family are naked
viruses that are built up of circular double-stranded DNA of
approximately5,000basepairssurroundedbyanicosahedral
capsid composed of the 3 structural proteins VP1, VP2, and
VP3. The viral genome contains a noncoding control region
(NCCR) that encompasses the origin of replication and the
transcriptional control region. On the opposite sites of the
NCCR are the early and late regions, which encode the early
proteins and the late proteins (Figure 1). The viral life cycle
can be divided in an early phase taking place before viral
DNA replication and a late phase occurring after replication
of the viral genome. Early in infection, the early proteins
large tumour antigen (LT-ag) and small tumour antigen (st-
ag) are expressed [1]. LT-ag is absolutely required for viral
replication, but is also involved in regulation of expression
of both the early and late genes. The LT-ag of diﬀerent
polyomaviruses can transform cells from diﬀerent species
and induce tumours in animal models and is therefore im-
plicated in the tumourigenic properties of polyomaviruses
(see further). St-ag has auxiliary functions, and its major
contribution in transformation relies on its ability to inac-
tivate protein phosphatase 2A. The early regions of some
polyomaviruses possess additional putative open reading
frames and encode other early proteins due to translation of
alternatively spliced transcripts [4] .T h el a t er e g i o ne n c o d e s
the capsid proteins VP1–3, while the late region of BKV, JCV,
and SV40 also encodes an agnoprotein. The exact function
of this protein remains incompletely understood. In contrast
to the other late proteins, it is not part of the viral particle,
but it seems to be implicated in viral maturation and release
[5, 6]. A ﬁfth late encoded protein, referred to as VP4, was
described for SV40. This protein enhances lysis of the host
cell and facilitates release of mature virus particles [7]. Lym-
photropic polyomavirus (LPV) and the recent described
human PyV KI, WU, Merkel cell polyomavirus (MCPyV),
trichodysplasia spinulosa-associated PyV (TSPyV), HPyV6,
HPyV7, and HPyV9 all lack an open reading frame (ORF)2 Pathology Research International
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Figure 1: Functional organization of the HPyV genome. The viral genome consists of a circular dsDNA of ∼5,000 base pairs. It can be divid-
ed into the noncoding control region (NCCR) ﬂanked by the early and late regions. The NCCR encompasses the origin of replication and
the early and late promoter elements. The early region, predominantly expressed before viral DNA replication, encodes the large T-antigen
(LT-ag) and small t-antigen (st-ag). The late region is expressed late in the viral life cycle and codes for the capsid proteins VP1, VP2, and
VP3. Some HPyV encode additional early proteins and the late protein, agnoprotein. The early and late genes are transcribed in opposite
direction and from complementary DNA strands.
correspondingtoVP4,whileBKVandJCVcontainaputative
VP4 ORF but the expression has not yet been conﬁrmed
(Table 1). The genomes of SV40, BKV, JCV, and MCPyV en-
code a miRNA that downregulates LT-ag expression levels
(reviewed in [8]). Cells expressing SV40 miRNA are less
susceptible to cytotoxic T cells and trigger less cytokine ex-
pression than cells infected with an SV40 mutant lacking
miRNA. Hence, miRNA-mediated downregulation of LT-ag
levels may allow the virus to escape the immune system (re-
viewed in [8]). Whether BKV, JCV, and MCPyV miRNAs
exert the same function remains to be tested. Viral-encoded
miRNA for LPV, WUPyV, KIPyV, TSPyV, HPyV6, HPyV7,
and HPyV9 has not been reported so far.
Until2006,BKvirusandJCvirus,namedaftertheinitials
of the patients from which they were ﬁrst isolated, were
the only two real human polyomaviruses (HPyV) known,
while simian virus 40 (SV40) also seems to circulate in
the human population. Lymphotropic polyomavirus (LPV),
another monkey polyomavirus, may also infect man as
speciﬁc antibodies against the major capsid protein VP1
were present in 15% of the blood samples from healthy
individuals, and LPV DNA has been detected in blood of
immunosuppressed and healthy subjects [9–11]. BK virus
(BKV) and JC virus (JCV) are ubiquitous in the human
population with up to 90% and 60%, respectively, of the
adults having antibodies against these viruses [9, 12]. SV40
s e e m st ob el e s sc o m m o nwi t ho n l ya r o u n d2 %o ft h eh u m a n
population showing anti-SV40 antibodies [9]. In 2007, two
new human polyomaviruses were described. One virus was
identiﬁed by a research group at the Karolinska Institute,
Sweden and they named the virus KI [13]. The other virus
was isolated by researchers from the Washington University
and they referred to the new virus as WU [14]. The HPyV KI
and WU are closely related, but are more diﬀerent from the
previously known BKV and JCV. In addition to amino acid
sequence diﬀerences between the viral proteins, KI and WU
lackaputativeagnoprotein.Bothvirusesarealsocommonin
the human population with seropositivity varying between
55% and 90% [9, 15, 16]. Shortly after the discovery
of HPyV KI and WU, a third new HPyV was reported.
In 2008, Feng et al. identiﬁed this new polyomavirus in
Merkel cell carcinoma tissue and hence named it Merkel
cell polyomavirus (MCPyV) [17]. Using improved rolling
circle ampliﬁcation techniques resulted in the discovery of
three novel HPyV. These viruses were isolated from the
skin and were named HPyV-6, HPyV-7, and trichodysplasia
spinulosa-associated virus [18, 19]. This year, another new
human polyomavirus wasisolated by PCR using degenerated
VP1 primers. This virus, tentatively named HPyV9, shows
highest homology with LPV [20].
2. The Oncoproteinsof HumanPolyomaviruses
All HPyV known to date encode proteins with oncogenic
properties in cell culture and animal models. The HPyV
oncoproteins include LT-ag and st-ag, while some alsoPathology Research International 3
Table 1: Comparison of the coding regions of the human polyomaviruses. The numbers refer to the number of amino acid residues, except
for the genome size, which is indicated in base pairs (bp). Absent means that a putative ORF for the protein is lacking at the corresponding
site in the genome. ELP: early leader protein; ORF: open reading frame.
HPyV Accession number Genome LT-ag st-ag Agno VP1 VP2 VP3 VP4 Alternative ORF miRNA
SV40 J02400.1 5243 708 174 62 364 352 234 125 17kT, SELP Present
BKV AB211371 5141 695 172 66 362 351 232 Putative ORF BELP Present
JCV J02226 5130 688 172 71 354 344 225 Putative ORF JELP, T
 
135,T
 
136,T
 
165 Present
LPV K02562.1 5270 697 189 Absent 368 356 237 Absent Not tested Not tested
KI EF127906 5040 641 191 Absent 378 400 257 Absent Not tested Not tested
WU EF444549 5229 648 194 Absent 369 415 272 Absent Not tested Not tested
MCPyV NC 010277 5387 818 186 Absent 423 241 196 Absent 57kT Present
HPyV6 HM011558 4926 669 190 Absent 387 336 215 Absent Not tested Not tested
HPyV7 HM011565 4949 671 193 Absent 380 329 209 Absent Not tested Not tested
TSPyV GU989205 5232 698/692∗ 199 Absent 376 313 195 Absent Not tested Not tested
HPyV9 HQ696595 5026 680 189 Absent 371 352 233 Absent Not tested Not tested
∗Two possible splice variants.
express additional early proteins and the regulatory late pro-
tein agnoprotein. The oncogenic properties will be brieﬂy
discussed in this section.
LT-ag is a multifunctional protein that is pivotal for the
viral life cycle of PyV because it is indispensible for viral
DNA replication and viral gene expression [1]. This protein
possesses oncogenic potentials: LT-ag can induce oncogenic
transformationofcells,cancausetumoursinanimalmodels,
and is expressed in human cancer cells containing the
virus (reviewed in [21, 22]). LT-ag is composed of sever-
al functional domains including the DnaJ domain, the
retinoblastoma (pRb) binding domain, the p53 binding
domain, a nuclear localization signal (NLS), a DNA binding
domain, and the helicase domain (see Figure 2). LT-ag can
induce oncogenic transformation through several mecha-
nisms (reviewed in [4, 21, 22]). The DnaJ domain can trans-
form cells through binding of HSc70, which aﬀects the cell
cycle and gene expression. Through its interactions with pRb
and p53, LT-ag perturbs cell cycle regulation. Moreover, LT-
ag has been shown to inhibit apoptosis, stimulate telomerase
a c t i v i t y ,m o d u l a t ep r o t e i nt u r n o v e r ,a ﬀect signalling path-
ways and gene expression, disturb chromosome ﬁdelity,
and induce angiogenesis. St-ag’s oncogenic properties are
mainly exerted by inhibiting PP2A [4, 21–23], while JCV
agnoprotein was shown to bind p53, to interfere with the
DNA repair protein Ku70, and to enhance transcription
of the cyclin-dependent kinase inhibitor p21Waf1/Cip1 gene
[5]. The additional early proteins expressed by some of the
human polyomaviruses may also contribute to oncogenesis
by dysregulating the cell cycle and inﬂuencing cellular gene
expression [4, 21].
3.HPyVandHumanDiseases
All known human polyomaviruses can act as oncoviruses
because they all encode the oncoproteins LT-ag and st-ag.
However, the role of BKV, JCV, and SV40 in human can-
cers remains controversial [24–27], while the role of LPV,
KIPyV, WUPyV, HPyV6, HPyV7, TSPyV, and HPyV9 in
human tumourigenesis has not been studied yet. The only
human PyV that is a candidate oncovirus is MCPyV, which
seems to be a causal factor in Merkel cell carcinoma (see
below). Human polyomaviruses seem to be harmless in im-
munocompetent individuals, but they can cause diseases
in immunocompromised patients. Mainly BKV, but also
JCV, is associated with polyomavirus nephropathy in renal
transplant recipients, while BKV is also associated with
hemorrhagic cystitis in bone marrow transplant patients
[28]. JCV is the etiological agent of progressive multifocal
leukoencephalopathy, while TSPyV may be the etiological
agentintrichodysplasiaspinulosa[28–30].Therole,ifany,of
LPV,KIPyV,WUPyV,HPyV6,HPyV7,andHPyV9inhuman
disease is not known [31]. In the next part of this paper, we
will discuss the tropism of human polyomaviruses for the
skin and elaborate their role in skin pathologies.
4.HumanPolyomaviruses:SkinTropismand
TheirRole inSkinPathologies
4.1. BKV, JCV, SV40. Earlier studies had demonstrated that
SV40 can infect and transform ﬁbroblasts derived from
human skin, human keratinocytes, and human melanocytes
and that transgenic mice expressing SV40, LT-ag in pigment
cells developed melanomas [32–36] .B K VD N Ac o u l db e
ampliﬁed in 25/33 (76%) of healthy skin tissue and BKV
and JCV, but not SV40 LT-ag DNA sequences were detected
in Kaposi’s sarcoma skin lesions [37]. In a recent report,
BKV DNA was detected in skin lesions from a bone marrow
transplant patient that developed hemorrhagic cystitis. The
skinlesionsresolvedafter5daysoftreatmentwithcidovir,an
antipolyomavirus drug, suggesting that a polyomavirus was
involved as a causal agent [38]. Furthermore, epidemiologi-
cal studies have indicated that immunosuppressed renal
transplant patients, a condition that favours reactivation of
BKV, have ∼20-fold higher incidence of developing cancer,
including skin cancer ([39], reviewed in [28]). These obser-
vations suggest that SV40, BKV, and JCV can infect the skin
and may even be involved in human skin cancer. However,4 Pathology Research International
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Figure 2: Functional domains of PyV LT-ag. The DnaJ domain (DnaJ) binds Hsc70, while the pRb pocket with the motif LXCXE binds the
retinoblastoma family members pRb, p107, and p130. NLS: nuclear localization signal; Zn: Zn-ﬁnger.
several reports decline the skin as a natural site for re-
plication and an etiological role for these viruses in skin
malignancies. An early study using Southern blotting had
failed to detect BKV DNA in one normal skin, in 3 skin
tumours, and in two melanoma cell lines [40]. Tumour
biopsies from eight patients with lymphoepithelioma-like
carcinoma conﬁned to the skin (face, scalp, or retroauricular
area) were all negative for SV40 [41], and Gellrich and co-
workers failed to detect BKV, JCV, and SV40 LT-ag DNA
by PCR in skin biopsies from 20 primary cutaneous B cell
lymphoma patients [42]. Thirty-eight paraﬃn-embedded
samples prepared from formalin ﬁxed melanomas collected
from body surfaces completely sheltered from the sun, the
so called extracutaneous melanomas, were investigated for
the presence of SV40, BKV, and JCV LT-antigen DNA by
nested PCR. The extracutaneous melanomas were derived
from the anal canal (n = 12), anus-rectum (n = 4), nasal
cavity (n = 6), vulva (n = 6), vagina-cervix (n = 4),
tongue (1), penis (1), subungual site (2), skin (1), and oral
cavity(1).Allsampleswerenegativeforallthreeviruses[43].
Another group also failed to detect BKV and JCV in skin
carcinomas obtained from 27 patients [44]. Taken together,
these ﬁndings jeopardize a role for the skin as a natural habi-
tat for SV40, BKV, and JCV.
4.2. LPV. Lymphotropic polyomavirus (LPV) was originally
identiﬁed as a monkey virus, but recent reports indicate that
this virus may infect humans. Indeed, 15–20% of adults
are seropositive for LPV antibodies, while <10% of the
blood samples obtained from healthy individuals and im-
munosuppressed patients were positive for LPV DNA [9–
11, 45–47]. So far, no reports have been published on the
presence of LPV in skin and its possible association with
skin diseases has not been addressed. However, the high LPV
seroprevalence may indicate that LPV has a serologically re-
lated counterpart [48]. This could be the new HPyV9 iso-
l a t e db yS c u d aa n dc o w o r k e r s( s e eSection 4.7;[ 20]).
4.3. KIPyV and WUPyV. Serological studies using VP1
capsomere-based ELISA have shown that infections with
the polyomaviruses KI and WU are very general in the
human population. Seropositivity varies between 55 and
90% and between 64 and 97.5% for KIPyV and WUPyV, res-
pectively (reviewed in [47]). The genuine host cells for both
viruses have not been established, but viral DNA has been
detected in blood, brain, central nervous system, lungs, and
tonsils (reviewed in [47]). No KIPyV or WUPyV DNA was
detected in one case of skin with neuroendocrine tumour
[49], while all 36 examined melanoma biopsies were also
negative for these two viruses [50]. Moreover, using an im-
provedrollingcircleampliﬁcationtechnique,Schowalterand
colleagues were able to isolate MCPyV and the new human
polyomaviruses HPyV6 and HPyV7 in skin samples, but the
authors did not report the ﬁnding of KIPyV or WUPyV [18].
Although a small number of individuals have been screened
so far, KIPyV and WUPyV do not seem to possess skin tro-
pism.
4.4. MCPyV
4.4.1. Merkel Cell, Merkel Cell Carcinoma, and MCPyV.
Merkel cells, originally described by Friedrich Merkel in
1875, are primarily located in the basal layer of the epidermal
cells near the end of axons. These cells are especially dense
in the skin of the limbs and face and around hair follicles.
Their role remains incompletely understood, but they may
function as mechanoreceptors or chemoreceptors (reviewed
in [51, 52]). Merkel cell carcinoma (MCC) is a rare but ag-
gressive skin cancer of neuroendocrine origin [53–56]. MCC
is extremely unusual before the age of 50 (∼5% of the cases)
and people at risk include those with fair skin, excessive
UVlightexposure,andimmunosuppressedpatients[55–57].
The incidence rate is 0.44 cases per 100,000 individuals in
the USA and 0.15 cases per 100,000 individuals in Japan.
The number of MCC cases has, however, tripled the last
15 years [58, 59]. In 2008, Feng and colleagues detected
sequences resembling LT-ag of polyomavirus in Merkel cell
carcinoma transcriptomes consisting of >380,000 cDNA
sequences obtained by pyrosequencing [17]. The authors
succeeded in cloning and sequencing the entire genome of
this virus, which turned out to be a novel polyomavirus.
This new polyomavirus was commonly found in Merkel cell
carcinoma (MCC) samples and therefore named Merkel cell
polyomavirus (MCPyV) [17]. After the original isolation of
this virus in MCC, a large number of studies have been
performed worldwide to look for MCPyV DNA in MCC.
Results from these studies show that approximately 80% of
the examined MCC samples contain MCPyV DNA, strongly
suggesting that MCPyV is a candidate etiological agent in the
development of MCC (see further). Although MCC occurs
most commonly in the skin, it has also been reported in sun-
protected sites such as the oral and nasal mucosa, vulva, andPathology Research International 5
penis. In a case report, MCPyV DNA and LT-ag expression
weredetectedinapatientwithnasopharyngealMCC,bothin
the primary tumour and in a lymph node metastasis, show-
ing that MCPyV may also be an etiological factor in these
types of MCC [60].
4.4.2. MCPyV and Cell Tropism. MCPyV infection is prob-
ably not restricted to Merkel cells because these cells make
up <1% of the cells in the epidermis, yet MCPyV virions
are being shed from the skin at high numbers [18]. This
strongly suggests that more common cells in the epidermis
like keratinocytes and/or melanocytes are involved in the
production of virions [18]. Transient transfection studies
in the human keratinocyte cell line HaCaT with a reporter
plasmid encoding luciferase under control of the MCPyV
NCCR showed that the MCPyV promoter/enhancer region
is functional in these cells, but the presence of MCPyV in
keratinocytes has not been investigated, while no MCPyV
DNA was detected in melanocytes [50, 61] .H e n c e ,ar o l e
for these two cell types as reservoirs for MCPyV remains to
be established. In two independent studies, MCPyV DNA
was detected in eyebrow hairs in 50% of the tested subjects
[19, 62]. This high prevalence in eyebrow hairs may suggest
that hair bulbs are a reservoir for MCPyV. MCPyV DNA was
also detected in warts of the skin from immunocompetent
and immunosuppressed patients, as well as in various skin
lesions from a renal transplant patient. However, only a
minority of the patients (≤10%) were MCPyV DNA positive
and no LT-ag expression was found [44]. Numerous studies
have addressed the cell tropism of MCPyV mainly by
performing PCR with MCPyV speciﬁc primers on diﬀerent
cell types and tissues. Using this technique, MCPyV DNA
was found in nasal swabs, oral cavity, oesophagus, blood,
tonsil biopsies, gall bladder, appendix, liver, lung, lymphoid,
and intestine tissue of healthy individuals ([17, 63–70],
reviewed in [47]). In blood of one psoriasis patient who was
diagnosed with MCC and of one renal transplant recipient
who had developed actinic keratoses, seborrheic keratoses,
and nonmelanoma skin cancer patient, MCPyV DNA was
exclusively detected in inﬂammatory monocytes, suggesting
that MCPyV may persist in and spread through these cells
[71]. However, for all studies, the number of MCPyV-DNA-
positive samples was very low and a limited number of
samples were investigated, making conclusions as to whether
these cells represent initial sites of infection or sites of
persistence preliminary.
Erickson and colleagues set out to identify the cellular
receptor for MCPyV in order to better understand the cell
tropismofthisvirus.Theauthorsdemonstratedthatpuriﬁed
MCPyV VP1 protein could assemble into pentamers, but
not into virus-like particles. Such VP1 pentamers bound
to liposomes containing ganglioside GT1b, but not GM1
(i.e., the receptor for SV40) or GD1a (i.e., the mouse
polyomavirus receptor), while a very weak binding to GD1b
(i.e., the receptor for BKV) was observed [72]. This result
indicates that ganglioside GT1b is a putative receptor for
MCPyV. The ﬁndings suggest that MCPyV has diﬀerent host
cell targets than the other HPyV. The binding of MCPyV
to its target receptor may be more complicated. The studies
were done with pentamers and not intact virions, which may
have a diﬀerent conformation and hence diﬀerent binding
requirement. Moreover, a coreceptor may be necessary for
optimal binding. These aspects may explain why the authors
found that MCPyV pentamers could bind to HeLa (human
cervical cancer carcinoma cells) and HEK293T (adenovirus-
transformed human embryonal kidney cells that express
SV40 LT-ag) cells, which may not be genuine target cells for
MCPyV. Indeed, MCPyV has not been detected in cervical
or kidney tissue so far and MCPyV viruria is a rare event,
indicating that the kidneys may not be an in vivo reservoir
[17, 49, 50, 73, 74]. Moreover, GT1b is particularly abundant
in neuronal cell membranes, but MCPyV DNA has not been
ampliﬁed in cerebrospinal ﬂuid, brain tumours, or tumours
of the central nervous system [17, 43, 75, 76], indicating that
these cell types lack the appropriate coreceptor for MCPyV.
4.4.3. MCPyV as the Causal Factor for MCC. The ﬁnding
that 80% of the tested MCC are positive for MCPyV DNA
raises the possibility that MCPyV is a candidate etiological
agent in the development of MCC (reviewed in [47]). On the
other hand, several groups have demonstrated the presence
of MCPyV DNA in skin of healthy subjects, but also in
skin biopsies adjacent to MCC [17, 44, 62, 69, 77, 78].
Moreover, serological studies demonstrated that MCPyV
infection occurs early in life and that up to 84% of healthy
adults have antibodies against this virus, indicating that
MCPyV infection is common in the human population
[9, 15, 18, 46, 79, 80]. The high seroprevalence of MCPyV
in healthy subjects is underscored by the high incidence with
which MCPyV DNA, complete genomes, or virus particles
have been found in skin swabs, skin biopsies, and plucked
eyebrowhairsofhealthysubjects[18,19,62].Twoskinswabs
collected approximately 3 months apart from 16 volunteers
all tested MCPyV DNA positive and contained ∼2 × 106
genome equivalents/mL of gradient material obtained from
the skin swab specimen. These ﬁndings indicate that healthy
individualsarechronicallyinfectedwithMCPyVandthatthe
virusiscontinuouslyreleasedfromtheskin[18].Skintoskin
contact may therefore be one way to horizontally transmit
the virus and may explain the high seroprevalence in the
human population. So, what argues for a role of MCPyV in
MCC besides the high incidence of MCPyV positive MCC?
First, small cell lung carcinoma (SCLC) is morphologically
similar to MCC, yet no MCPyV DNA could be detected
in this tumour [49, 81, 82]. However, two groups have
succeeded in amplifying MCPyV DNA from SCLC, but the
frequency of positive samples is much lower than in MCC
(7.5%; n = 30 and 39%; n = 18) [83, 84]. Secondly, the
reported numbers of virus genome copies per MCC tumour
cellaremuchhigherthanthehighestvalueobtainedforother
MCPyV DNA positive tissues.
Loyo and her colleagues estimated the relative viral
copy number in diﬀerent tissues by arbitrary assuming that
MCC had an average of 10 MCPyV genome copies per cell
(range 175 to 0.05). Based on this assumption, saliva had an
average of 0.13 genome copies per cell, while lung, kidney,6 Pathology Research International
bladder, and prostate had <0.001 genome copies per cell
[69]. Nonmelanoma skin cancer samples had on average 5-
fold lower viral load than MCPyV-positive MCC [85]. Shuda
and colleagues conﬁrmed these results as they found that
MCPyV-positive MCC contained ∼1–15 genome copies/cell,
while the copy numbers in lymphoid cells from diﬀerent
patient groups that did not have MCC were 100- to 10,000-
fold lower [67]. Other groups reported numbers of genome
copies per MCC tumour cell or MCC cell line varying
between 3 × 10−4 and 4 × 103 genome copies per cell, and
0.02and10forMCCcelllines[73,74,86–91].Despiteexten-
sive variation, which could be due to the detection method
used, non-MCC tissues always contained less genome copies
per cell than MCC samples in the corresponding study. It
should be noted that the numbers estimated may actually
be higher because the MCC tissue samples also contain
nontumourcells,makingaccuratedeterminationofthevirus
genome copy number per tumour cell diﬃcult. Another
indication that MCPyV may be involved in MCC is that the
viral genome is clonally integrated in MCC tumour cells and
the primary tumours as well as metastatic cells carry the
same integration pattern, while viral DNA is episomal in
other MCPyV-positive cells [17, 74, 89, 92]. MCPyV DNA
seems to be randomly integrated at a single integration site
in the diﬀerent MCC [74]. Another strong clue pointing to
a causal role of MCPyV in the development of MCC is that
knockdown of the early proteins in MCPyV-positive MCC
cell lines by RNA interference initiates growth arrest and cell
death [93]. Finally, the antibody titres against MCPyV VP1
are on average ∼60-fold higher in MCC patients compared
to healthy controls. This is not the result of VP1 expressed
on the cell surface of the tumour cells, as MCC tumour cells
did not express detectable levels of VP1, but rather by an
unusuallyimmunogenic MCPyVinfection [46]. It is unlikely
that the MCPyV-positive MCC patients newly acquired an
infection because the MCPyV IgM antibodies were not sig-
niﬁcantly diﬀerent from the other subjects [79]. Serum
antibodies recognizing MCPyV capsid protein are detectable
athightitreinnearlyallMCCpatientsaswellasinmorethan
half of the general population. Accordingly, they provide
limited value as a diagnostic marker for MCPyV-positive
MCC. Paulson and colleagues found that antibodies against
MCPyV LT-ag and st-ag are more speciﬁcally associated with
MCC. These antibodies were present in only 0.9% of 530
control serum samples tested, whereas among 205 MCC
cases 40.5% of the samples were positive. Additionally, they
found that titres of LT-ag and st-ag antibodies dropped
rapidly in patients whose cancer did not reoccur whereas
they rose in cases that experienced progressive disease [94].
Taken together, MCPyV is now considered as a causative fac-
tor in MCC.
4.4.4. Mechanisms by Which MCPyC Induces MCC. MCPyV-
positive MCC possess speciﬁc traits compared to other
MCPyV-positive cells. As mentioned in the previous section,
the MCPyV genome is integrated in the host genome of
MCC cells. MCPyV genomes in non-MCC tissues are wild-
type genomes, while the integrated genomes in MCC carry
deletions in the VP1 gene and speciﬁc mutation patterns in
the LT-ag gene resulting in expression of truncated LT-ag
[17, 71, 74, 91]. This C-terminal-truncated LT-ag retains the
regions with predicted oncogenic potentials such as the DnaJ
domain and the retinoblastoma binding pocket, but fails to
support viral DNA replication [92]. Despite the expression
of replication-deﬁcient LT-ag in MCC, Wetzels and her
colleagues could demonstrate the presence of viral particles
in one of their MCC samples by electron microscopy [82].
This suggests the expression of a functional LT-ag since
LT-agisindispensableforviralDNAreplicationanddiscloses
that not all MCPyV-positive MCC express truncated LT-ag.
Interestingly, Sastre-Garau and coworkers characterized one
MCC case where the tumour cells contained both integrated
and episomal MCPyV DNA. The episomal DNA did not
carry mutations that could lead to truncated LT-ag protein,
while the integrated viral genome encoded a C-terminal
truncated LT-ag [74]. A similar scenario might have been the
caseforthepatientstudiedbyWetzelsetal.,henceexplaining
the presence of viral particles in MCPyV-positive MCC
cells of this patient. Yet, another group reported sequences
encoding full length LT-ag in MCC, jeopardizing the role
of truncated LT-ag in the development of MCC [95]. In
conclusion, MCPyV-positive MCC can express truncated
LT-ag or/and full-length LT-ag as a result of integrated
MCPyV genome encoding mutated LT-ag or/and episomal
genome copies encoding wild-type LT-ag, respectively. The
discrepancy in the ﬁnding of viral sequences encoding
truncated LT-ag or complete LT-ag may be a result of the
limitation of the PCR method, which will selectively amplify
the most abundant template. Numerous MCC samples
should be investigated with methods distinguishing between
integrated and episomal DNA to establish whether coexist-
ence of integrated and episomal MCPyV DNA is common or
exceptional.
Mutated MCPyV genomes have also been isolated from
non-MCC tissues. One full-length genome isolated from a
Kaposi’s sarcoma specimen encoded a truncated LT-ag that
retained the DnaJ and pRb domains, but lacked the helicase
region [73]. Schowalter and her colleagues used a rolling
circle ampliﬁcation strategy to isolate full-length MCPyV
DNA shed from the skin of healthy volunteers [18]. Dworkin
et al. sequenced LT-ag in MCPyV-positive squamous cell
carcinoma (SCC) samples. All SSC samples (19 out of 19)
displayed the same missense mutation in LT-ag (Glu259 into
stop codon) which resulted in a truncated protein that still
contained the DnaJ- and Rb-binding domains, but lacked
the complete helicase domain. Seven out of nine normal
adjacent skin samples also carry this mutation, while a
MCPyV-positive mouthwash sample did not possess this
mutation [96]. Fourteen out of 35 (40%) subjects yielded
complete MCPyV genomes, and sequence analysis revealed
that they were wild-type genomes, except for one isolate
which had a frame shift in the coding sequence of st-ag
resulting in a truncation of carboxy terminal 15 amino
acids. The functional consequences are not known, but the
corresponding residues in SV40 st-ag are not necessary for
the interaction with PP2A, suggesting that this MCPyV
mutant st-ag still can interact with PP2A [97].Pathology Research International 7
MCC cells also express higher levels of LT-ag than other
MCPyV-positive cells [67]. This is the consequence of the
higher genome copy number in MCC, but may also result
from mutations in the NCCR which enhance the transcrip-
tionalactivityoftheMCPyVpromoterandoftheintegration
of the genome. The latter event may place the MCPyV
promoter in a chromosomal environment which is more
favourable for transcription than the MCPyV in its natural
state, that is, as part of the episomal viral genome. Studies
that test these assumptions are lacking so far.
Since not all MCC are positive for MCPyV, virus-de-
pendentand-independentoncogenicpathwaysmaybeoper-
ational in the tumourigenesis of MCC [15, 98]. Bhatia
and coworkers showed that MCPyV-positive MCC with re-
latively high MCPyV DNA levels (i.e., 0.06–1.2 genome
copies/cell) had signiﬁcantly higher retinoblastoma and ter-
minal deoxynucleotide transferase, but signiﬁcantly lower
p53 protein levels than MCC that had low viral genome copy
numbers (i.e., 0.0005–0.0035 genome copies/cell) or were
MCPyV negative. This may indicate that MCC may arise
through diﬀerent oncogenic pathways [88]. Another expla-
nation may be that additional modiﬁcations, most probably
mutations in host genes, may be more important or are nece-
ssary for MCC development in addition to the common
event of MCPyV infection. In favour of this assumption is
that there is a long time interval in the development of MCC
(median age = 70 years) and the initial exposure to MCPyV
(early childhood) [15, 80, 99]. The contribution of other, yet
unknown factors is further supported by the ﬁndings that
there is a female predominance of MCPyV-positive MCC
patients. Kassem et al. found that 13 out of 20 (65%) of
their male MCC patients were MCPyV positive, while 17 out
of 19 (89%) female MCC patients contained MCPyV DNA
in the tumour tissue [100]. Another study reported that 19
out of 33 (74%) female MCC patients were MCPyV DNA-
positive patients, while 7 out of 14 (50%) of the male MCC
patients were MCPyV DNA positive [101]. This indicates a
female dominance, but the total number of MCPyV-positive
patients in these studies is relative low.
4.4.5. MCPyV and Other Skin Diseases. MCPyV DNA could
also be ampliﬁed in specimens of other malignant and non-
malignant skin tissues, including Kaposi’s sarcoma, malig-
nant melanoma, basal cell carcinoma, atypical ﬁbroxan-
thoma,keratoacanthoma,squamouscellcarcinoma,Bowen’s
disease, psoriasis, actinic porokeratosis, trichoblastoma, and
seborrheic keratoses. However, MCPyV DNA was found
signiﬁcantly less often in these non-MCC skin cancers than
in MCC and the viral DNA load was also signiﬁcantly lower
[44, 62, 68, 73, 78, 85, 96, 101–107].
Not all studies could conﬁrm the presence of MCPyV
in some of these other skin diseases. Three groups failed to
detect MCPyV DNA in diﬀerent non-MCC skin malignan-
cies [74, 101, 107]. Based on the low incidence of MCPyV
DNA in basal cell carcinoma (12.5% in [102]), the limited
number of samples tested by Andres and collaborators (n =
1 1 ) ,b yS a s t r ea n dc o l l e a g u e s( n = 13), and by Murakami
and coworkers (n = 10) could explain why these researchers
didnotdetectMCPyVDNA.Immunohistochemicalstaining
of 7 combined primary skin tumours with mixed features
of squamous and neuroendocrinic carcinoma with a speciﬁc
MCPyV LT-ag monoclonal was negative for all samples [76].
This may indicate that MCPyV is not implicated in this skin
cancer,butdeﬁnitiveconclusionscannotbedrawnfromsuch
a small sample size.
4.5. HPyV-6 and HPyV-7. Schowalter and coworkers identi-
ﬁed the two new polyomaviruses HPyV6 and HPyV7 in skin
swabs. Complete HPyV6 (resp., HPyV7) genomes were clon-
ed from a total of 5/35 (resp., 4/35 individuals). Similar to
M C P y V ,v i r i o n ss e e m e dt ob es h e dc o n t i n u o u s l yi nH P y V 6 -
and HPyV7-positive individuals; however, at a much lower
number than MCPyV, approximately 5,000 HPyV6 genome
equivalents/mL of gradient material were obtained from the
skinswabmaterial,andanumbertoolowtoallowconﬁ-dent
interpretation for HPyV7, while ∼2 × 106 MCPyV ge-nome
equivalents/mL of gradient material were obtained. Sero-
prevalencewas69%forHPyV6and35%forHPyV7(n = 95)
[18]. Thus, both HPyV6 and HPyV7 are two new human
polyomaviruses with skin tropism that seem to be common
in the human population and are shed continuously in
infected persons. So far, no clinical symp-toms have been
associated with these viruses.
4.6. Trichodysplasia Spinulosa-Associated Virus. Trichodys-
plasia spinulosa (TS) is a rare skin disease exclusively found
in immunocompromised patients and characterized by the
development of follicular papules and keratin spines known
as spicules. Electron microscopy studies showed the pre-
sence of polyomavirus-like particles in skin biopsies of
TS patients, suggesting an etiological role polyomavirus
for this disease ([108–112], reviewed in [30]). In 2010,
van der Meijden and her colleagues succeeded in cloning
and completely sequencing the viral genome from spicules
obtained from a 15-year-old male transplant patient with TS
[19]. Sequence analysis conﬁrmed that this virus is a new
member of the Polyomaviridae. The authors provisionally
called it TS-associated polyomavirus (TSPyV). The authors
investigated plucked eyebrows from 69 immunocompetent
renal transplant recipients and were able to obtain TSPyV
PCR products in three of the patients (4%). The estimated
copy number of viral genomes was much lower than in
their TS patient (<1 genome copy/cell versus ∼104 genome
copies/cell). Although a limited number of patients were
tested, TSPyV may represent an occasional infection in im-
munocompromised patients with no signs of TS. Another
recent case report conﬁrmed the presence of TSPyV, but
not MCPyV in skin biopsies from a 7-year-old girl with
Down syndrome and pre-B-acute lymphoblastic leukaemia
who also suﬀered from TS [30]. Both ﬁndings indicate that
TSPyV may be implicated in TS. However, viral particles are
not always detected in specimens of TS patients [113]. This
negative ﬁnding could be the result of low sensitivity of the
method used, poor quality of the sample, or indeed the lack
of TSPyV. On the other hand, conformation of TSPyV DNA
by PCR in a specimen does not imply that infectious virus
particlesarepresent.Therefore,additionalstudiesonalarger
number of TS patients, as well as healthy controls and other8 Pathology Research International
patient groups are required to establish a possible relation to
the occurrence of TSPyV and its causal role in TS and other
skin diseases.
4.7. HPyV9. T h el a s tm e m b e rt oj o i nt h ef a m i l yo fh u m a n
polyomaviruses was isolated from the serum of a kidney
transplant patient under immunosuppressive treatment us-
ing degenerated primers against conserved regions in the
VP1 genes of known PyV [20]. Sequencing of the total
genome revealed that this new virus, HPyV9, bears closest
similarity to LPV. The 597 clinical samples in which HPyV9
was originally detected with the degenerated primers were
then tested with HPyV9-speciﬁc primers and HPyV9 DNA
was ampliﬁed in only 4 other samples (serum of a patient
withPML,serumofakidneytransplantpatient,wholeblood
of an acute myeloid leukaemia patient, and urine of a kidney
transplant patient). Hence, the prevalence of this virus in the
human population seems to be low. Further studies are re-
quired to identify the sites of HPyV9 replication and per-
sistence and to determine the pathogenic potentials of this
virus.
5. Conclusions andFuturePerspectives
The human polyomaviruses HPyV6, HPyV7, and MCPyV
seemtobecommonintheskinandevenshowahightropism
for the skin. Their continuous shedding from the skin faci-
litates their transmission to other individuals and may
explain the high seroprevalence, at least for MCPyV. Sero-
epidemiological studies on HPyV6 and HPyV7, two derma-
totropic polyomaviruses, have not been performed, but as
these two viruses are also chronically shed from the skin,
they may be highly common in the human population as
well. While a strong causal link between MCPyV and Merkel
cell carcinoma has been established in recent years and
TSPyV may be a causal factor in TS, diseases associated
with HPyV6 and HPyV7 infection remain unidentiﬁed. To
conﬁrm an etiological role of TSPyV in TS, large cohorts
of TS patients should be examined. It is also possible that
TSPyV is latently infecting healthy individuals and that the
immunosuppressed conditions in TS patients trigger reacti-
vation of this virus in these patients. Whether active TSPyV
replication occurs in other immunocompromised patients
such as organ transplant recipients, AIDS patients, and
autoimmune disease patients remains to be examined. The
development of new techniques such as deep sequencing and
the improvement of existing techniques such as rolling circle
ampliﬁcation have led and may lead to the identiﬁcation of
several new polyomaviruses and generated a resurgence of
interest in these viruses and their pathogenic potentials, in-
cluding skin diseases. Once again, the medical world may
be challenged with the development of eﬃcient therapies
against human viruses causing health problems.
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